← back to search

Josef Vormoor

Princess Máxima Center ·
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, and Cancer Genomics and Diagnostics.
h-index
46
citations
12,801
works
261
NIH funding
primary concept
email

Recent publications

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma
European Journal of Cancer 2022cited by 68position: middledoi
Epigenetic regulator genes direct lineage switching in  <i>MLL/AF4</i> leukemia
Blood 2022cited by 67position: middledoi
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’
European Journal of Cancer 2022cited by 58position: middledoi
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement
Haematologica 2022cited by 22position: middledoi
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
Leukemia 2021cited by 46position: middledoi
Epidemiology and biology of relapse after stem cell transplantation
Bone Marrow Transplantation 2018cited by 150position: middledoi
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
Cancer Cell 2018cited by 124position: middledoi
Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
Future Oncology 2018cited by 63position: lastdoi
The MLL recombinome of acute leukemias in 2017
Leukemia 2017cited by 685position: middledoi
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
Nature Reviews Clinical Oncology 2017cited by 77position: middledoi
From class waivers to precision medicine in paediatric oncology
The Lancet Oncology 2017cited by 52position: middledoi
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition
Blood 2014cited by 256position: middledoi
The MLL recombinome of acute leukemias in 2013
Leukemia 2013cited by 507position: middledoi
Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia
Leukemia 2013cited by 61position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jean‐Pierre Bourquin · Novartis (Switzerland)4 papers (2017–2022)C. Michel Zwaan · Erasmus MC4 papers (2017–2022)Alex Elder · Newcastle University2 papers (2013–2018)Lia Gore · The University of Texas Health Science Center at Houston2 papers (2018–2022)Stefan M. Pfister · Université du Québec2 papers (2017–2017)Birgit Geoerger · Institut Gustave Roussy2 papers (2017–2017)Olaf Heidenreich · Newcastle University2 papers (2013–2018)Pamela Kearns · Utrecht University2 papers (2017–2017)François Doz · Institut Curie2 papers (2017–2017)Gilles Vassal · Université Paris-Sud2 papers (2017–2017)Bruce Morland · Birmingham Women’s and Children’s NHS Foundation Trust2 papers (2017–2017)Arend von Stackelberg · Charité - Universitätsmedizin Berlin2 papers (2014–2022)Michela Casanova · Fondazione IRCCS Istituto Nazionale dei Tumori2 papers (2017–2017)André Baruchel · HIPI - Immunologie humaine, physiopathologie et immunithérapie2 papers (2017–2022) · 1 papers (2021–2021)Daniel A. Morgenstern · Hospital for Sick Children1 papers (2018–2018) · 1 papers (2013–2013)Matthias Eder · German Cancer Research Center1 papers (2013–2013)Rob Pieters · Utrecht University1 papers (2021–2021)Jana Hof · Charité - Universitätsmedizin Berlin1 papers (2014–2014)